Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Psychiatry

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints

Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints
1 month ago
Share

Aptinyx Reports NYX-783 Significantly Improved PTSD Symptoms in Phase 2 Trial

Aptinyx reported positive results from a phase 2 trial evaluating NYX-783 versus placebo in patients with post-traumatic stress disorder (PTSD). […]

Aptinyx Reports NYX-783 Significantly Improved PTSD Symptoms in Phase 2 Trial
5 months ago
Share

Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD

Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]

Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD
5 months ago
Share

Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia

Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are […]

Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia
7 months ago
Share

ACADIA Reports Phase 3 CLARITY Study of Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Fails to Reach Primary Endpoint

ACADIA Pharmaceuticals announced top-line results from its Phase 3 CLARITY study which combined two identical studies evaluating the efficacy, safety […]

ACADIA Reports Phase 3 CLARITY Study of Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Fails to Reach Primary Endpoint
8 months ago
Share

BioXcel Therapeutics Meets All Endpoints in Two Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

BioXcel Therapeutics announced that BXCL501, a proprietary sublingual thin film of dexmedetomidine, met the primary and secondary endpoints in the […]

BioXcel Therapeutics Meets All Endpoints in Two Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
8 months ago
Share

Biohaven Releases Positive Data from Phase 2/3 Study of Troriluzole in the Treatment of Obsessive-Compulsive Disorder (OCD)

Biohaven Pharmaceuticals announced positive topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). […]

Biohaven Releases Positive Data from Phase 23 Study of Troriluzole in the Treatment of Obsessive-Compulsive Disorder (OCD)
9 months ago
Share

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression

Axsome Therapeutics announced top-line results from the phase 3 STRIDE-1 trial evaluating AXS-05 versus active comparator bupropion for treatment of […]

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression
11 months ago
Share

Journal of Clinical Psychiatry Publishes Data from Alkermes Phase 3 ENLIGHTEN-1 Study of ALKS 3831 for Schizophrenia

Alkermes announced that the peer-reviewed publication, Journal of Clinical Psychiatry, has published data from the phase 3 ENLIGHTEN-1 clinical trial […]

Journal of Clinical Psychiatry Publishes Data from Alkermes Phase 3 ENLIGHTEN-1 Study of ALKS 3831 for Schizophrenia
1 year ago
Share

FDA Approves Expanded Access Application for MDMA-Assisted Psychotherapy in PTSD Patients

The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to […]

FDA Approves Expanded Access Application for MDMA-Assisted Psychotherapy in PTSD Patients
1 year ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.